Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with both gastrointestinal and significant cutaneous adverse events.
- GLP-1RAs are prescribed for type 2 diabetes and obesity, indicating their growing therapeutic role.
- Gastrointestinal adverse events are the most commonly recognized side effects of GLP-1RAs.
- Cutaneous adverse events represent a substantial proportion of total adverse reactions linked to GLP-1RAs.
Simplified